Document is current
Any future updates will be listed below
-
Authors
Waldschmidt, Johannes https://orcid.org/0000-0001-5340-1818
Fandrei, David
Hecker, Judith S.
Meggendorfer, Manja https://orcid.org/0000-0002-9038-3265
Truger, Marietta
Reinhard, Franz
Shibru, Benjamin
Högner, Marion
Gebauer, Anna
Köppel, Max
Müller, Heiko
Jung, Johannes https://orcid.org/0000-0003-0137-7929
Teschner, Daniel https://orcid.org/0000-0001-7351-8060
Topp, Max S.
Purcarea, Anna
Vučinić, Vladan
Haferlach, Torsten https://orcid.org/0000-0003-0196-2837
Bassermann, Florian
Platzbecker, Uwe https://orcid.org/0000-0003-1863-3239
Einsele, Hermann https://orcid.org/0000-0002-7680-0819
Haferlach, Claudia https://orcid.org/0000-0002-6333-5049
Kortüm, K. Martin https://orcid.org/0000-0002-7011-0286
Metzeler, Klaus H. https://orcid.org/0000-0003-3920-7490
Merz, Maximilian
Götze, Katharina S.
Rasche, Leo https://orcid.org/0000-0002-9536-9649
-
Funding
Funding for this research was provided by:
José Carreras Leukämie-Stiftung (04PSD/2024)
José Carreras Leukämie-Stiftung (04PSD/2024)
Bundesministerium für Bildung und Forschung
European Hematology Association
Deutsche Forschungsgemeinschaft (TRR 331/Z02)
Deutsche Forschungsgemeinschaft (TRR 331/Z02)
Deutsche Forschungsgemeinschaft (TRR 387/1 – 514894665)
Deutsche Krebshilfe
- License Information
-
More Information
Article History
Received: 31 January 2026
Revised: 20 February 2026
Accepted: 12 March 2026
First Online: 24 March 2026
Competing interests
: The authors declare the following competing interests: JMW reports personal fees or consultancy for Johnson & Johnson, Sanofi, Takeda, Pfizer, Oncopeptides, Menarini-Stemline, Skyline Dx, Abbvie, Amgen and GSK, and research support from BMS. JSH received consulting and/or speaker fees and/or travel accommodation expenses from Johnson & Johnson, BMS, Kite/Gilead, Abbvie, Servier, Novartis, Roche, Iovance, Imatics, Philogen, Boehringer Ingelheim, Immunocore, Autolus and Kyverna. VV reports personal fees from BMS, Johnson & Johnson, Novartis, Gilead/Kite. KMK reports personal fees from Celgene, BMS, AbbVie, GSK, and Takeda; grants and personal fees from Johnson & Johnson. CH and TH are owners of MLL Munich Leukemia Laboratory. MT, MM and HM are current employees of MLL Munich Leukemia Laboratory. FB received honoraria and/or travel/accommodation expenses from BMS, AbbVie, Amgen and Johnson & Johnson. UP served as consultant for Johnson & Johnson, AbbVie, Amgen, BMS, Curis, Geron, and Novartis; received honoraria from Johnson & Johnson and Curis; received research funding from Johnson & Johnson, AbbVie, Amgen, BMS, Curis, Merck, and Novartis; held membership on an entity’s board of directors or advisory committees with BMS and the Myelodysplastic Syndromes Foundation; and received travel support from BMS. HE reports grants and other support from Johnson & Johnson, BMS, Amgen, GSK, and Sanofi, as well as further support from Takeda and Novartis. MM reports honoraria from Amgen, Bristol Myers Squibb (BMS), Celgene, Gilead, Johnson & Johnson, Stemline, SpringWorks, and Takeda; reports membership on an entity’s board of directors or advisory committees for Amgen, BMS, Celgene, Gilead, Johnson & Johnson, Stemline, SpringWorks, and Takeda; and received research funding from Amgen, BMS, Celgene, Gilead, Johnson & Johnson, Stemline, SpringWorks, and Takeda. LR reports personal fees from BMS, Johnson & Johnson, Pfizer, Amgen, GSK and Sanofi. All other authors declare no competing interests.
